

# Global Obsessive-Compulsive Disorder Market: Focus on Drug Class, Indication, Country and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/G7D40876F533EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: G7D40876F533EN

## Abstracts

The Obsessive-Compulsive Disorder (OCD) market is a rapidly evolving sector, driven by increasing awareness, improved diagnostic rates, and the growing adoption of both pharmacological and device-based therapies. OCD, characterized by persistent, intrusive thoughts (obsessions) and repetitive behaviors (compulsions), affects an estimated 1-3% of the global population. The treatment landscape is largely dominated by Selective Serotonin Reuptake Inhibitors (SSRIs), such as fluoxetine and sertraline, which are typically considered first-line pharmacotherapies, with clomipramine as an alternative for treatment-resistant cases. Furthermore, cognitive-behavioral therapy (CBT), specifically Exposure and Response Prevention (ERP), remains a cornerstone of non-pharmacological interventions. In recent years, device-based therapies, particularly Deep Transcranial Magnetic Stimulation (Deep TMS), have gained traction, offering new options for patients who are resistant to conventional treatment.

This growth is fueled by rising prevalence rates, with countries like the U.S., Europe, and Japan accounting for the largest shares of the market. Epidemiological data suggests a significant proportion of patients remain undiagnosed or untreated due to factors like stigma, limited access to specialists, and under-recognition of the disorder, especially in low-to-middle-income countries.

Key drivers of market growth include the increasing availability of telehealth and telemedicine services, which facilitate easier access to both pharmacotherapy and ERP, as well as a greater understanding of OCD's chronic nature, leading to longer treatment durations and maintenance therapy. Deep TMS, which has been FDA-approved for OCD since 2018, adds a new dimension to treatment for patients who have not responded to medications, with clinics in North America and Europe leading the way in

its adoption. However, the market faces several restraints, including variability in reimbursement, the complexity of treatment regimens, and generic erosion of legacy medications, which could limit revenue growth in certain segments. Moreover, challenges related to limited access to ERP therapy and regional disparities in mental health infrastructure hinder the potential to reach the full addressable market.

Geographically, the North American market holds the largest share, driven by well-established healthcare systems, high diagnosis rates, and the prevalence of FDA-cleared devices. Europe follows, with substantial growth driven by an expanding number of clinics offering device-based treatments and comprehensive coverage under public health systems. The Asia-Pacific region presents both a growing opportunity due to large populations and a rising focus on mental health but is also challenged by access issues, including a shortage of trained therapists and stigma surrounding mental health disorders. In summary, while the OCD market faces some challenges related to accessibility, it is poised for significant growth, driven by innovative treatments and an expanding global focus on mental health care.

The competitive landscape of the Obsessive-Compulsive Disorder (OCD) market is shaped by a blend of pharmaceutical treatments, neurostimulation devices, and psychotherapy options. Companies and organizations in this market are targeting the growing need for effective, long-term treatments for OCD, which remains a chronic and often debilitating condition. The primary players in the pharmaceutical segment are companies that manufacture Selective Serotonin Reuptake Inhibitors (SSRIs) and other traditional pharmacotherapies. SSRIs remain the cornerstone of pharmacological treatment due to their first-line status in clinical guidelines, driven by their efficacy in addressing the serotonin imbalance believed to underpin OCD.

Companies in the space are continually innovating to meet the unmet needs of patients with OCD, and as the market grows, players that can provide integrated treatment solutions and expand patient access will likely have a competitive advantage. As the demand for OCD treatment options increases globally, driven by higher diagnosis rates and greater awareness, there will be increasing opportunities for both drug companies and device manufacturers to capture a share of this growing market.

## **Market Segmentation:**

Segmentation 1: by Drug Class

Selective Serotonin Reuptake Inhibitors

Serotonin-Norepinephrine Reuptake Inhibitors

Serotonin Antagonist and Reuptake Inhibitors

Others

### Segmentation 2: by Disease Indication

Major Depressive Disorder

Anxiety Disorders

Attention Deficit Hyperactivity Disorder

Others

### Segmentation 3: by Region

North America

Europe

Asia-Pacific

Rest of the World

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

## Contents

Executive Summary  
Scope and Definition  
Market/Product Definition  
Key Questions Answered  
Analysis and Forecast Note

### **1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER MARKET: INDUSTRY OUTLOOK**

- 1.1 Industry Outlook
  - 1.1.1 Market Introduction
  - 1.1.2 Epidemiological Analysis
  - 1.1.3 Introduction on Obsessive-Compulsive Disorder Market
    - 1.1.3.1 Market Definition
    - 1.1.3.2 Diagnostic Algorithm
    - 1.1.3.3 Treatment Guidelines
  - 1.1.4 Regulatory Landscape of Obsessive-Compulsive Disorder Market
    - 1.1.4.1 Legal Requirement and Framework in the U.S.
    - 1.1.4.2 Legal Requirement and Framework in the E.U.
    - 1.1.4.3 Legal Requirement and Framework in Japan
    - 1.1.4.4 Legal Requirement and Framework in Rest-of-the-World
- 1.2 Market Dynamics
  - 1.2.1 Impact Analysis
  - 1.2.2 Market Drivers
  - 1.2.3 Market Restraint
  - 1.2.4 Market Opportunities

### **2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER MARKET (BY DRUG CLASS), \$MILLION, 2024-2035**

- 2.1 Overview
  - 2.1.1 Selective Serotonin Reuptake Inhibitors
  - 2.1.2 Serotonin-Norepinephrine Reuptake Inhibitors
  - 2.1.3 Serotonin Antagonist and Reuptake Inhibitors
  - 2.1.4 Others

### **3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER MARKET (BY DISEASE**

**INDICATION), \$MILLION, 2024-2035**

## 3.1 Overview

- 3.1.1 Major Depressive Disorder
- 3.1.2 Anxiety Disorders
- 3.1.3 Attention Deficit Hyperactivity Disorder
- 3.1.4 Others

**4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER MARKET, BY REGION, \$MILLION, 2024-2035**

## 4.1 Overview

## 4.2 North America

- 4.2.1 Key Market Participants in North America
- 4.2.2 Business Drivers
- 4.2.3 Business Challenges
- 4.2.4 Market Sizing and Forecast
  - 4.2.4.1 North America Obsessive-Compulsive Disorder Market, by Country
    - 4.2.4.1.1 U.S.
    - 4.2.4.1.2 Canada

## 4.3 Europe

- 4.3.1 Key Market Participants in Europe
- 4.3.2 Business Drivers
- 4.3.3 Business Challenges
  - 4.3.3.1 Europe Obsessive-Compulsive Disorder Market, by Country
    - 4.3.3.1.1 Germany
    - 4.3.3.1.2 U.K.
    - 4.3.3.1.3 France
    - 4.3.3.1.4 Italy
    - 4.3.3.1.5 Spain
    - 4.3.3.1.6 Rest-of-Europe

## 4.4 Asia-Pacific

- 4.4.1 Key Market Participants in Asia-Pacific
- 4.4.2 Business Drivers
- 4.4.3 Business Challenges
- 4.4.4 Market Sizing and Forecast
  - 4.4.4.1 Asia-Pacific Obsessive-Compulsive Disorder Market, by Country
    - 4.4.4.1.1 Japan
    - 4.4.4.1.2 China

- 4.4.4.1.3 India
- 4.4.4.1.4 Australia
- 4.4.4.1.5 South Korea
- 4.4.4.1.6 Rest-of-APAC

#### 4.5 Rest-of-the-world

- 4.5.1 Key Market Participants in Rest-of-the-world
- 4.5.2 Business Drivers
- 4.5.3 Business Challenges
- 4.5.4 Market Sizing and Forecast

### **5. COMPETITIVE LANDSCAPE AND COMPANY PROFILES**

#### 5.1 Competitive Landscape

- 5.1.1 Overview
- 5.1.2 Key Developments and Strategies
  - 5.1.2.1 Funding Activities
  - 5.1.2.2 Mergers and Acquisitions
  - 5.1.2.3 Regulatory Approvals
  - 5.1.2.4 Partnerships, Collaborations and Business Expansions
- 5.1.3 Growth-Share Analysis (by Company)

#### 5.2 Company Profiles

- 5.2.1 Pfizer, Inc.
  - 5.2.1.1 Overview
  - 5.2.1.2 Product Portfolio
  - 5.2.1.3 Target Customers
  - 5.2.1.4 Key Personnel
  - 5.2.1.5 Analyst View
- 5.2.2 Novartis AG
  - 5.2.2.1 Overview
  - 5.2.2.2 Product Portfolio
  - 5.2.2.3 Target Customers
  - 5.2.2.4 Key Personnel
  - 5.2.2.5 Analyst View
- 5.2.3 Amgen, Inc.
  - 5.2.3.1 Overview
  - 5.2.3.2 Product Portfolio
  - 5.2.3.3 Target Customers
  - 5.2.3.4 Key Personnel
  - 5.2.3.5 Analyst View

- 5.2.4 Boehringer Ingelheim
  - 5.2.4.1 Overview
  - 5.2.4.2 Product Portfolio
  - 5.2.4.3 Target Customers
  - 5.2.4.4 Key Personnel
  - 5.2.4.5 Analyst View
- 5.2.5 GlaxoSmithKline plc
  - 5.2.5.1 Overview
  - 5.2.5.2 Product Portfolio
  - 5.2.5.3 Target Customers
  - 5.2.5.4 Key Personnel
  - 5.2.5.5 Analyst View
- 5.2.6 Eli Lilly and Company
  - 5.2.6.1 Overview
  - 5.2.6.2 Product Portfolio
  - 5.2.6.3 Target Customers
  - 5.2.6.4 Key Personnel
  - 5.2.6.5 Analyst View
- 5.2.7 Jazz Pharmaceuticals
  - 5.2.7.1 Overview
  - 5.2.7.2 Product Portfolio
  - 5.2.7.3 Target Customers
  - 5.2.7.4 Key Personnel
  - 5.2.7.5 Analyst View
- 5.2.8 Apotex Inc.
  - 5.2.8.1 Overview
  - 5.2.8.2 Product Portfolio
  - 5.2.8.3 Target Customers
  - 5.2.8.4 Key Personnel
  - 5.2.8.5 Analyst View
- 5.2.9 H.Lundbeck A/S
  - 5.2.9.1 Overview
  - 5.2.9.2 Product Portfolio
  - 5.2.9.3 Target Customers
  - 5.2.9.4 Key Personnel
  - 5.2.9.5 Analyst View
- 5.2.10 Teva Pharmaceuticals Ltd.
  - 5.2.10.1 Overview
  - 5.2.10.2 Product Portfolio

5.2.10.3 Target Customers

5.2.10.4 Key Personnel

5.2.10.5 Analyst View

## **6. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Obsessive-Compulsive Disorder Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Obsessive-Compulsive Disorder Market, 2024 and 2035

Figure: Global Obsessive-Compulsive Disorder Market Key Trends, Impact Analysis, 2024-2035

Figure: North America Obsessive-Compulsive Disorder Market, \$Million, 2024-2035

Figure: Europe Obsessive-Compulsive Disorder Market, \$Million, 2024-2035

Figure: Asia-Pacific Obsessive-Compulsive Disorder Market, \$Million, 2024-2035

Figure: Rest-of-the-World Obsessive-Compulsive Disorder Market, \$Million, 2024-2035

## List Of Tables

### LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Obsessive-Compulsive Disorder Market (by Region), \$Million, 2024-2035

## I would like to order

Product name: Global Obsessive-Compulsive Disorder Market: Focus on Drug Class, Indication, Country and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/G7D40876F533EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7D40876F533EN.html>